Sigilon Therapeutics (NASDAQ: SGTX)
Some price data may be temporarily unavailable.
Sigilon Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sigilon Therapeutics Company Info
Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. Its program includes Rare Blood Disorders, Lysosomal Storage Diseases, and Endocrine and Other Chronic Diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.